The global spine biologics market is expected to reach $30.43 billion by 2034 due to factors including increased prevalence of spinal disorders, growing preference for minimally invasive procedures and favorable reimbursement policies.
In 2023, the spine biologics market was valued at $5.16 billion.
North America is expected to see the highest revenue share for spine biologics during the forecast period, and the Asia Pacific region is expected to grow at the fastest CAGR.
Key players identified by the research group include Medtronic, Stryker, Zimmer Biomet and Bioventus.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
